pubrio
Servier logo

Servier

Privately Held
+1
servier.com
製藥製造12,700+ employeesFounded 1998🇫🇷 法國

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

成立年份
1998
員工
12,700+
行業
製藥製造
公司類型
Privately Held
總部
🇫🇷Suresnes
專長
生物技術製藥製造研究與發展醫療保健及生命科學
8 / 22
活躍市場
1
新市場
BR
信心度
大多為早期訊號
-17%
動能
對比上一週期
32 / 100
擴張評分
發展中
階段5探索中17投入中
33 個訊號 · 過去 90 日

全球擴張

即時
JPTHMX
階段
探索中投入中進入中營運中
+19個市場已鎖定
已顯示 22 個中的 3 個

解鎖市場時間軸與訊號動態

活動脈搏

過去 90 日內有 34 個訊號。

過去 90 日
招聘
11-17%
招聘
市場推廣與公關
23-8%
廣告
產品與技術
0
無活動
+2個類別已鎖定
已顯示 5 個中的 3 個

市場進入時間軸

此公司進入各市場的次序 — 由最舊至最新

1
🇲🇽MX第 1st 個進入的市場 · 2023推進中
投入中
13 個訊號投入中 階段
2
🇹🇭TH第 2nd 個進入的市場 · 2024推進中
投入中
14 個訊號投入中 階段
3
🇯🇵JP第 3rd 個進入的市場 · 2025推進中
投入中
27 個訊號投入中 階段
+19個市場已鎖定
已顯示 22 個中的 3 個
目前階段投入中投入資源
信心度35%
開始追蹤於2023首個訊號

近期訊號

人手擴充🇯🇵 JP上星期

13 active postings

招聘🇯🇵 JP3星期前

Tibsovo Product Lead

註冊以查看完整訊號動態

值得了解

關於 Servier 的常見問題

關於 Servier 業務、市場及增長訊號的快速解答。

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

立即展開你的旅程

可以先用平台,也可以先聊聊

自行使用 Pubrio,或讓我們的團隊協助研究、挖掘潛在客戶,甚至串接資料。

Start Journey Image
pubrio

Pubrio 將 50+ 個在地來源的商業、人才與意圖數據全球化整合,讓 AI 與營收團隊掌握完整市場視野。

© 2026 Pubrio。版權所有。